Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
The platform is being introduced to expand access to treatments for people living with chronic conditions
Miels will formally assume the role on January 1, 2026
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Subscribe To Our Newsletter & Stay Updated